Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones

Alfonso Quintás-Cardama, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Several tyrosine kinase inhibitors (TKIs) are currently under development for the treatment of patients with chronic myelogenous leukemia (CML) resistant or intolerant of imatinib therapy, including nilotinib, dasatinib, and bosutinib. The current paradigm of TKI therapy involves a sequential use of these compounds, with imatinib invariably used as frontline therapy followed by either dasatinib or nilotinib on an empiric basis. A more sensible approach to this sequence is the selection of the TKI best suited to overcome the resistance conferred by BCR-ABL1 mutations detected at each time-point. As more TKIs are becoming available, the management of patients with CML will require degree of "finesse" to better match each patient with the best TKI available. This match is best made based on available in vitro data regarding the activity of each agent against each specific mutation. The case herein reported supports such strategy.

Original languageEnglish (US)
Pages (from-to)1313-1316
Number of pages4
JournalLeukemia Research
Issue number8
StatePublished - Aug 2008
Externally publishedYes


  • BCR-ABL1
  • Bosutinib
  • CML
  • Clones
  • Imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones'. Together they form a unique fingerprint.

Cite this